Andrew Gengos is the Chief Business Officer and Chief Financial Officer of our company. His responsibilities include leading business development, managing finance and accounting operations, and supporting equity and other financings. He joined AOBiome in January 2019. Mr. Gengos graduated from the Massachusetts Institute of Technology with a Bachelor of Science degree in Chemical Engineering and earned his Master of Business Administration degree from the UCLA Anderson School of Management.
Prior to joining the company, Mr. Gengos had over 25 years of biotechnology and life-science industry experience in strategy, business development, operations and finance. From 1991-1998, Mr. Gengos was a consultant at McKinsey & Company, a global management consulting firm. From 1999-2000, Mr. Gengos held various senior management roles including vice president of corporate development and strategy at Chiron Corporation, a California-based biotechnology company. From 2000-2002, Mr. Gengos was chief financial officer at Dynavax Technologies, a California-based biotechnology company. From 2002-2010, Mr. Gengos was vice president of strategy and corporate development at Amgen Inc., a California-based biotechnology company. While at Amgen, Mr. Gengos was responsible for managing acquisitions, licensing, spin outs, corporate venture capital, alliance management, and corporate strategy. From 2010-2012, Mr. Gengos was president, chief executive officer and a member of the board of directors of Neuraltus Pharmaceuticals, a California-based biotechnology company. From 2012-2016, Mr. Gengos was president, chief executive officer, and a member of the board of directors of ImmunoCellular Therapeutics, a California-based biotechnology company. From 2017-January 2019, Mr. Gengos was chief business officer and head of corporate development at Synlogic Inc., a Massachusetts-based biotechnology company.